Increased p‐tau is initially associated with Aβ deposition in asymptomatic individuals; further increases are seen in the symptomatic phases of AD, when overt NFT pathology is present in the brain and driving cognitive symptoms. This evidence concerns the gene MAPT and Alzheimer disease.